Results 261 to 270 of about 43,288,830 (344)
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Accuracy of nanopore sequencing technology for rapid diagnosis of tuberculous mediastinal and hilar lymphadenopathy using endobronchial ultrasound-guided transbronchial needle aspiration specimens: protocol for a systematic review and meta-analysis. [PDF]
BMJ OpenYu G, Du K, Shen Y, Ling Y, Zhong F.
europepmc +1 more source
Noticias de NACCS, vol. 39, no. 2, June 2010 [PDF]
, 2010 National Association for Chicana and Chicano Studies
core +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
A Systematic Review of Obstetric Mistreatment Among Women Living With HIV. [PDF]
Nurs Health SciEdeh J +4 more
europepmc +1 more source
Noticias de NACCS, vol. 29, no. 4, December 2002 [PDF]
, 2002 National Association for Chicana and Chicano Studies
core +1 more source